30Oct
30Oct
Carbonite backup comes to virtual machines
Now called Carbonite Server VM Edition, the latest expansion of Carbonite's backup capabilities signifies the vendor's strategic push into the midmarket. Read more >>
26Oct
Regroup Mass Notification Successfully Delivers Millions of Alerts During the Annual Great ShakeOut
During the event, more than 2 million alerts were sent to participants of the famous earthquake drill throughout the United States and Canada using multiple channels of communication. Read more >>
25Oct
Powered brace proves restoring arm functionality is no longer out of reach
Wearable technologies such as exosuits can enhance people’s baseline abilities by giving them the ability to walk further or lift more than they would ordinarily be able to. In some cases, this means helping non-disabled people to carry out tasks more efficiently. Where it’s more profound, however, is in helping people with disabilities to perform actions that might otherwise be impossible. This is where a powered brace called the MyoPro myoelectric arm orthosis excels. Manufactured by the wearable medical robotics company...
25Oct
BrandVerge Is Creating A Marketplace For Sponsored Content
Putting together a sponsored content program is a time-consuming headache for buyers and publishers. BrandVerge, a marketplace where buyers can browse publishers’ sponsored content options, aims to make it faster and easier to create sponsored content deals. The platform claims to shorten the deal-making process by an average of 67%. Read more >>
24Oct
Regroup Mass Notification Named Finalist in ‘ASTORS’ Homeland Security Awards Program
Award recognizes top vendors who create a more resilient nation by demonstrating a commitment to addressing current homeland security threats. Read more >>
23Oct
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company with the industry’s leading pipeline focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced continued favorable safety and tolerability profiles and further improvement in efficacy outcomes in open-label extensions (OLEs) of lenabasum Phase 2 studies in two rare and serious autoimmune diseases, systemic sclerosis (SSc) and dermatomyositis (DM). Read more >>
06Oct
Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment
Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum and might be used to treat any fibrotic disease, including cystic fibrosis (CF), the company announced in a press release. Read more >>
05Oct
When product development goes sideways (and how to fix it)
Product development going wrong? You may need a tiger team. By Jeff Champagne and Eric Claude, MPR Associates, Inc. We would all like for product development projects to go smoothly and predictably, but you know what they say about “the best-laid plans.” Robert Burns aside, when needed technologies do not integrate as easily as planned, hardware or software bugs crop up at the last minute (or worse, cause failures in the field), or project teams struggle to complete work on schedule, forward...
05Oct